Pfizer tops profit estimates as older drugs offset falling COVID sales, warns of revenue pressure ahead
Strong sales of older medicines like Eliquis lifted fourth-quarter profit, even as COVID-19 product revenue fades and patent expirations threaten future sales.
Copy link
By Torontoer Staff
Pfizer reported fourth-quarter adjusted earnings of US$0.66 per share, beating analysts' estimates of US$0.57, and posted total sales of US$17.56-billion, above the US$16.95-billion expected by the market. The results were powered by steady demand for established medicines even as sales of COVID-19 products continued to decline.
The quarter highlights a familiar trade-off for large drugmakers: revenue stability from older, high-volume products can mask looming pressures from patent expirations and shifting demand for pandemic-era vaccines and treatments.
Quarterly results at a glance
- Adjusted profit: US$0.66 per share, versus US$0.57 expected
- Total sales: US$17.56-billion, versus US$16.95-billion expected
- Key drivers: sustained sales of Eliquis, heart and oncology medicines
- Ongoing drag: lower demand for COVID-19 products
What lifted profit this quarter
Pfizer said older medicines, including blood thinner Eliquis and a range of cardiovascular and oncology drugs, provided the revenue needed to offset a continued decline in COVID-19 vaccine and treatment sales. Those established therapies tend to have more predictable demand, and several remain market leaders in their categories.
The challenges ahead: COVID declines and patent cliffs
While the quarter delivered a beat, Pfizer faces a multi-year revenue challenge. Sales of its COVID-19 products have tapered from pandemic peaks, and the company is staring down upcoming patent expirations for several major drugs. When patents expire, cheaper generics can enter the market and erode pricing and volume for branded medicines.
We do not expect to return to revenue growth until 2029.
Pfizer
That timeline, which Pfizer has flagged publicly, sets expectations for investors and underlines why the company is prioritising new product development and strategic deals.
How Pfizer plans to respond
Pfizer is banking on a pipeline of new medicines and recent acquisitions to refill revenue lines that will be weakened by generic competition. The company has pursued deals to add obesity treatments and other late-stage candidates that could become future blockbusters, and it continues to invest in heart disease and oncology programmes.
Success for that strategy depends on clinical and regulatory outcomes, as well as market uptake if approvals are secured. Timeline uncertainty means investors are watching guidance and pipeline milestones closely.
What to watch next
- Upcoming patent expirations and the timeline for generic entrants
- Performance and market rollouts for newly acquired obesity drugs
- Quarterly updates on COVID-19 product demand
- Clinical trial and regulatory news for late-stage candidates in the pipeline
Investors will also monitor margin trends, pricing pressure in key markets, and management commentary on cost structure and capital allocation as the company navigates a period of transition.
What this means for patients and markets
For patients, sustained demand for established drugs suggests continued availability of treatments for common conditions such as heart disease and cancer. Over time, patent expirations could lower costs as generics enter the market, though timing varies by drug and region.
For markets, Pfizer's results underline a broader theme in big pharma: predictable revenues from mature products can cushion earnings, but growth depends on a steady flow of successful new drugs or strategic acquisitions.
Pfizer delivered a stronger-than-expected quarter, but the company and its investors face a multi-year challenge as COVID-19 demand fades and patent expirations loom. The outcome will hinge on whether new products and deals can replace revenue gaps before generics take hold.
PfizerpharmaceuticalsearningsEliquisCOVID-19
